Acadia Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DR6.F | ATAI | NEU.AX | AXSM | B9A.F | PRAX | |
|---|---|---|---|---|---|---|
| Market cap | 3.26B | — | 2.95B | 7.21B | 2.45B | 7.95B |
| P/E (TTM) | 9.9 | — | 154.9 | — | 250.7 | — |
| Forward P/E | -20.6 | — | 38.9 | 34.0 | — | -30.0 |
| Price/book | 3.0 | — | 8.8 | 68.3 | 1.2 | 5.9 |
| Dividend yield | — | — | 1.52% | — | 0.68% | — |
| 1-year change | −7.49% | — | −2.22% | +2.89% | +5.23% | +70.38% |
| Today | +2.85% | 0.00% | +17.49% | −1.87% | −0.29% | +1.53% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All DR6.F news ›Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect -- Narrowly missed primary endpoint of SAPS H+D…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such... NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims…
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program – Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undisclosed…
ACADIA Pharmaceuticals (ACAD) – Analysts’ Weekly Ratings Changes
Several brokerages have updated their recommendations and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) in the last few weeks: 10/19/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC.…
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Keeps “Buy” Rating at Needham & Company LLC
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a report issued on Monday, Benzinga reports. They presently have a $35.00 price objective on the…
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to “Hold” at Wall Street Zen
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Monday, Wall Street Zen reports. View Our Latest Stock Report on ACAD ACADIA…
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to “Neutral” at UBS Group
Posted by Kim Johansen on Oct 13th, 2026 ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by investment analysts at UBS Group from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday,…
Bronstein, Gewirtz & Grossman, LLC Encourages ACADIA Pharmaceuticals Inc. (ACAD) Shareholders to Inquire about Securities Investigation
ACCESS Newswire Bronstein, Gewirtz & Grossman, LLC Encourages ACADIA Pharmaceuticals Inc. (ACAD) Shareholders to Inquire about Securities Investigation Monday, 12
Acadia Pharmaceuticals | Science & Technology
Cummings, J. et al. (2014) ‘Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial’, The Lancet, 383(9916), pp. 533–540. Glaze, D.G. et al. (2019) ‘A Double-Blind, Randomized,…
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX) and Satellos Bioscience (MSLE) with bullish sentiments. Canaccord Genuity…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net8
- accessnewswire.com2
- markets.businessinsider.com2
- prnewswire.com2
- gurufocus.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.